Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- RYTM
- Price
- 108.36
- Stock movement up
- +1.07 (1.02%)
- Company name
- Rhythm Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 7.05B
- Ent value
- 7.36B
- Price/Sales
- 62.69
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -3.71%
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- 73.73%
- 3 year return (CAGR)
- -
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2025-12-04
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
RYTM does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 62.69 |
| Price to Book | - |
| EV to Sales | 65.40 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 66.74M |
| EPS (TTM) | -2.99 |
| FCF per share (TTM) | -1.70 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 174.33M |
| Gross profit (TTM) | 155.86M |
| Operating income (TTM) | -186.21M |
| Net income (TTM) | -192.33M |
| EPS (TTM) | -2.99 |
| EPS (1y forward) | -2.62 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 89.40% |
| Operating margin (TTM) | -106.81% |
| Profit margin (TTM) | -110.32% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 52.08M |
| Net receivables | 33.03M |
| Total current assets | 494.80M |
| Goodwill | 0.00 |
| Intangible assets | 5.53M |
| Property, plant and equipment | 3.40M |
| Total assets | 506.87M |
| Accounts payable | 13.63M |
| Short/Current long term debt | 151.00M |
| Total current liabilities | 104.27M |
| Total liabilities | 358.06M |
| Shareholder's equity | 148.82M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -109.13M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -109.13M |
| Dividends paid (TTM) | 4.05M |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -129.24% |
| Return on Assets | -37.94% |
| Return on Invested Capital | -128.70% |
| Cash Return on Invested Capital | -73.03% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 104.63 |
| Daily high | 107.57 |
| Daily low | 102.76 |
| Daily Volume | 553K |
| All-time high | 117.62 |
| 1y analyst estimate | 139.00 |
| Beta | 1.97 |
| EPS (TTM) | -2.99 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 4 Mar 2026 |
Downside potential
Loading...
Downside potential data
| RYTM | S&P500 | |
| Current price drop from All-time high | -7.87% | -0.89% |
| Highest price drop | -30.27% | -19.00% |
| Date of highest drop | 4 Apr 2025 | 8 Apr 2025 |
| Avg drop from high | -9.47% | -2.49% |
| Avg time to new high | 11 days | 6 days |
| Max time to new high | 142 days | 89 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
7.05B
Marketcap category
Mid-cap
Description
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. The company was founded in 2008 and is headquartered in Boston, Massachusetts.
Employees
283
Website
Investor relations
-
SEC filings
CEO
Hunter C. Smith
Country
USA
City
Boston
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page